Jerome Chal, PhD

Dr. Chal joined Myeloid in April 2022 as our Senior Vice President, Head of CMC. Dr. Chal brings to Myeloid over twenty years of experience in the biotechnology industry, with a focus on CMC leadership across multiple cell and gene therapies, with landmark achievements in the field. Prior to Myeloid, Dr. Chal was Executive Director, Analytical Sciences at Vertex Pharmaceuticals, where he provided strategic leadership to a multi-site and multi-department CMC organization across the T1D, blood disorders (Casgevy) and DMD programs, along with end-to-end implementation of all analytical CMC activities from preclinical to pivotal stage. Prior to Vertex, Dr. Chal was Director, Cell and Analytical Development at Semma Therapeutics, where he directed cell, process and assay development programs for cell therapy products. Prior to that, Dr. Chal held positions of increasing responsibility at Coyne Scientific, IGBMC (Strasbourg, France), and was a faculty scientist at Brigham and Women’s Hospital and Harvard Medical School. Dr. Chal received his MS in Biology-Biochemistry from ENS Paris, Paris 7 University, an MS in Molecular and Cellular Developmental Biology from Sorbonne University, and a Ph.D. in Stem Cell and Developmental Biology from Sorbonne University/Stowers Institute (Kansas City, MO). Dr. Chal is a decorated scientist with multiple patents and over twenty peer-reviewed publications in the fields of biotechnology and cell and gene therapy.